NEW YORK CITY, Sept. 30, 2022/ PRNewswire/– AIkido Pharma Inc. (NASDAQ: AIKI) (” AIkido” or the “Business”) today supplied an upgrade on the $3 million share redeemed program (the “Share Repurchase Program”) accredited by the Business’s Board of Supervisors on January 21, 2022.

In the structure of the Share Repurchase Program, the Business has actually bought 303,886 typical shares in the duration from January 21, 2022 as much as and also consisting of September 29, 2022. The rate per share variety for the shares bought was $5.34 to $6.97.

Added shares might be bought every so often in free market purchases, or various other ways based on Guideline 10b5-1 of the Stocks Exchange Act of 1934, as modified (the “Exchange Act”), and also Guideline 10b -18 of the Exchange Act. The timing, variety of shares bought, and also rates spent for the supply under this program will certainly rely on basic company and also market problems in addition to company and also regulative constraints, consisting of blackout duration constraints.

Regarding AIkido Pharma Inc

. AIkido Pharma Inc. was originally developed in 1967 and also is a biotechnology Business with a varied profile of small-molecule anticancer and also antiviral rehabs. The Business’s system includes trademarked modern technology from leading colleges and also scientists, and also we are presently in the procedure of establishing a cutting-edge restorative medicine system with solid collaborations with globe popular universities, consisting of The College of Texas at Austin and also College of Maryland at Baltimore. Our varied pipe of rehabs consists of treatments for pancreatic cancer cells, prostate cancer cells. We are continuously looking for to expand our pipe to deal with unmet clinical requirements in oncology. The Business is likewise establishing a broad-spectrum antiviral system that might possibly hinder duplication of several infections consisting of Flu infection, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and also Marburg infection.

Progressive Declarations

Specific declarations in this news release comprise “progressive declarations” within the significance of the government safety and securities regulations. Words such as “may,” “might,” “will,” “should,” “think,” “anticipate,” “prepare for,” “quote,” “proceed,” “forecast,” “projection,” “job,” “strategy,” “plan” or comparable expressions, or declarations relating to intent, idea, or existing assumptions, are progressive declarations. While the Business thinks these progressive declarations are sensible, unnecessary dependence must not be put on any type of such progressive declarations, which are based upon info readily available to us on the day of this launch. These progressive declarations are based upon existing price quotes and also presumptions and also go through different threats and also unpredictabilities, consisting of without restriction those stated in the Business’s filings with the SEC, not restricted to Threat Elements associating with its company had therein. Hence, real outcomes can be materially various. The Business specifically disclaims any type of responsibility to upgrade or modify declarations whether as an outcome of brand-new info, future occasions or otherwise, other than as called for by legislation.

Get in touch with:

Financier Relations:

Hayden IR

Brett Maas, Handling Companion

Phone: (646) 536-7331

Email:[email protected]

AIkido Pharma Inc.:.

Phone: 212-745-1373.

Email:[email protected]

Resource AIkido Pharma Inc